XML 40 R30.htm IDEA: XBRL DOCUMENT v2.4.0.6
Derivative Financial Instruments (Tables)
3 Months Ended
Mar. 31, 2013
Derivative Financial Instruments  
Schedule of derivative financial instruments
        
     March 31, 2013 (1) December 31, 2012 (2)
 ZAR     
  Notional  423,634  423,634
  Carrying Amount/Fair Value  14,841  20,441
        
 COP     
  Notional  101,250,000  101,250,000
  Carrying Amount/Fair Value  7,398,809  5,356,377
        
        
 (1)The interest rate swap agreements are denominated in ZAR and COP and have an aggregate notional amount and fair value of $101.1 million and $5.6 million, respectively, as of March 31, 2013.
 (2)The interest rate swap agreements are denominated in ZAR and COP and have an aggregate notional amount and fair value of $107.3 million and $5.4 million, respectively, as of December 31, 2012.
        
Schedule of interest rate swap agreements' impact on other comprehensive income
            
 Three Months Ended March 31, 2013
 Amount of Gain/(Loss) Recognized in OCI on Derivatives (Effective Portion) Location of Gain/(Loss) Reclassified from Accumulated OCI into Income (Effective Portion) Amount of Gain/(Loss) Reclassified from Accumulated OCI into Income (Effective Portion) Location of Gain/(Loss) Recognized in Income on Derivative (Ineffective Portion and Amount Excluded from Effectiveness Testing) Gain/(Loss) Recognized in Income on Derivative (Ineffective Portion and Amount Excluded from Effectiveness Testing)
 $ (933) Interest expense $ (608) N/A N/A
            
 Three Months Ended March 31, 2012
 Amount of Gain/(Loss) Recognized in OCI on Derivatives (Effective Portion) Location of Gain/(Loss) Reclassified from Accumulated OCI into Income (Effective Portion) Amount of Gain/(Loss) Reclassified from Accumulated OCI into Income (Effective Portion) Location of Gain/(Loss) Recognized in Income on Derivative (Ineffective Portion and Amount Excluded from Effectiveness Testing) Gain/(Loss) Recognized in Income on Derivative (Ineffective Portion and Amount Excluded from Effectiveness Testing)
 $ (535) Interest expense $ (152) N/A N/A